Published Studies Related to Risperdal Consta (Risperidone)
Well-designed clinical trials related to Risperdal Consta (Risperidone)
Risperidone versus risperidone plus sodium valproate for treatment of bipolar
disorders: a randomized, double-blind clinical-trial. [2014]
A head-to-head comparison of aripiprazole and risperidone for safety and treating
autistic disorders, a randomized double blind clinical trial. [2014]
Paliperidone palmitate versus risperidone long-acting injection in
markedly-to-severely ill schizophrenia subjects: onset of efficacy with
recommended initiation regimens. [2014]
Double-blind, placebo-controlled trial of risperidone plus amantadine in children
with autism: a 10-week randomized study. [2013]
Memantine add-on to risperidone for treatment of negative symptoms in patients
with stable schizophrenia: randomized, double-blind, placebo-controlled study. [2013]
Risperidone dosing in children and adolescents with autistic disorder: a
double-blind, placebo-controlled study. [2013]
Memantine as adjunctive treatment to risperidone in children with autistic
disorder: a randomized, double-blind, placebo-controlled trial. [2013]
Characteristics of responders and non-responders to risperidone monotherapy or
placebo in co-occurring bipolar disorder and anxiety disorder. [2013]
Efficacy of risperidone in children with disruptive behavioural disorders. [2013]
Double-blind placebo-controlled randomized efficacy and safety trial of add-on
treatment of dimebon plus risperidone in schizophrenic patients during transition
from acute psychotic episode to remission. [2012]
Cost and cost-effectiveness in a randomized trial of long-acting risperidone for
schizophrenia. [2012]
Early treatment with risperidone for subsyndromal delirium after on-pump cardiac
surgery in the elderly: a randomized trial. [2012]
A double-blind placebo controlled trial of Ginkgo biloba added to risperidone in
patients with autistic disorders. [2012]
Therapeutic effects of cerebrolysin added to risperidone in patients with
schizophrenia dominated by negative symptoms. [2012]
Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide
in schizophrenia. [2012]
Risperidone and olanzapine versus another first generation antipsychotic in
patients with schizophrenia inadequately responsive to first generation
antipsychotics. [2012]
A placebo-controlled study of the modafinil added to risperidone in chronic
schizophrenia. [2012]
Co-morbid Disruptive Behavior Disorder and Aggression Predict Functional Outcomes and Differential Response to Risperidone Versus Divalproex in Pharmacotherapy for Pediatric Bipolar Disorder. [2011.12.02]
A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia. [2011.09.24]
A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study. [2011.09]
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). [2011.09]
Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes. [2011.08.15]
Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial. [2011.08.03]
A double-blind, placebo-controlled study of traditional Chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia. [2011.08]
Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder. [2011.08]
Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder: fMRI outcomes. [2011.07.30]
A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. [2011.06.01]
Weight changes and their associations with demographic and clinical characteristics in risperidone maintenance treatment for schizophrenia. [2011.06]
An open-label trial of risperidone in children and adolescents with severe mood dysregulation. [2011.06]
Comparative pharmacokinetics and bioequivalence of two tablet formulations of 2 mg risperidone in healthy Thai male volunteers. [2011.06]
Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison. [2011.06]
Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men. [2011.06]
Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone. [2011.06]
Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: Comparing treatment with risperidone and haloperidol. [2011.05.13]
An open randomized pilot trial on the differential effects of aripiprazole versus risperidone on anhedonia and subjective well-being. [2011.05]
Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia. [2011.05]
Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study. [2011.04.15]
Long-acting risperidone and oral antipsychotics in unstable schizophrenia. [2011.03.03]
Olanzapine vs. risperidone in treating aggressive behaviours in adults with intellectual disability: a single blind study. [2011.02]
Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial. [2011.02]
Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. [2011.02]
Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. [2011.01.15]
A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. [2011.01.15]
Co-morbid disruptive behavior disorder and aggression predict functional outcomes
and differential response to risperidone versus divalproex in pharmacotherapy for
pediatric bipolar disorder. [2011]
A double-blind, placebo-controlled study of risperidone for the treatment of
adolescents and young adults with anorexia nervosa: a pilot study. [2011]
A pilot study of the efficacy and safety of paroxetine augmented with
risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese
patients with treatment-resistant major depression. [2011]
Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic
military service-related PTSD: a randomized trial. [2011]
A double-blind, placebo-controlled study of traditional Chinese medicine
sarsasapogenin added to risperidone in patients with negative symptoms dominated
schizophrenia. [2011]
Long acting injection versus oral risperidone in first-episode schizophrenia:
differential impact on white matter myelination trajectory. [2011]
Double-blind randomized trial of risperidone versus divalproex in pediatric
bipolar disorder: fMRI outcomes. [2011]
A comparative study of paliperidone palmitate and risperidone long-acting
injectable therapy in schizophrenia. [2011]
Mirtazapine augmentation enhances cognitive and reduces negative symptoms in
schizophrenia patients treated with risperidone: a randomized controlled trial. [2011]
A double-blind, randomized study comparing the efficacy and safety of sertindole
and risperidone in patients with treatment-resistant schizophrenia. [2011]
Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial. [2010.12]
A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia. [2010.12]
Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone. [2010.12]
Relative bioavailability of two oral formulations of risperidone 2 mg: A single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Brazilian volunteers. [2010.11]
Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. [2010.10.01]
Esquire trial: efficacy and adverse effects of quetiapine versus risperidone in first-episode schizophrenia. [2010.10]
Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. [2010.10]
Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. [2010.10]
Comparison of olanzapine and risperidone in the EMBLEM Study: translation of randomized controlled trial findings into clinical practice. [2010.09]
Relative bioavailability and pharmacokinetic comparison of two 2-mg risperidone tablet formulations: A single dose, randomized-sequence, double-blind, 2-way crossover study in healthy male volunteers in Thailand. [2010.09]
Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder. [2010.09]
Comparative bioavailability of two risperidone orodispersible tablet products after single dose administration. [2010.09]
Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial. [2010.08.04]
A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. [2010.07]
Risperidone versus olanzapine for the treatment of delirium. [2010.06]
Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial. [2010.06]
Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone. [2010.05]
A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia. [2010.04.20]
Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. [2010.03.24]
Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. [2010.02.01]
Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: a double-blind, randomized clinical trial. [2010.02]
The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. [2010.02]
Clinical overview of children with mucopolysaccharidosis type III A and effect of Risperidone treatment on children and their mothers psychological status. [2010.02]
Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms. [2010.01]
A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents. [2010.01]
Association of 9-hydroxy risperidone concentrations with risk of switching or
discontinuation in the clinical antipsychotic trial of intervention
effectiveness-Alzheimer's disease trial. [2010]
A double-blind, randomized, and placebo-controlled trial of buspirone added to
risperidone in patients with chronic schizophrenia. [2010]
A randomized, double-blind comparison of risperidone versus low-dose risperidone
plus low-dose haloperidol in treating schizophrenia. [2010]
Double-blind, placebo-controlled trial of risperidone plus topiramate in children
with autistic disorder. [2010]
Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: a randomized open, prospective study. [2010]
Risperidone long-acting injectable monotherapy in the maintenance treatment of
bipolar I disorder. [2010]
Comparison of topiramate and risperidone for the treatment of behavioral
disturbances of patients with Alzheimer disease: a double-blind, randomized
clinical trial. [2010]
The effect of mirtazapine add on therapy to risperidone in the treatment of
schizophrenia: a double-blind randomized placebo-controlled trial. [2010]
Cognitive function with long-term risperidone in children and adolescents with disruptive behavior disorder. [2009.12]
A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. [2009.12]
A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. [2009.12]
Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. [2009.11]
Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study. [2009.11]
Effect of Warm-Supplementing Kidney Yang (WSKY) added to risperidone on quality of life in patients with schizophrenia: a randomized controlled trial. [2009.11]
A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. [2009.10]
A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. [2009.10]
Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia. [2009.10]
Effect of Warm-Supplementing Kidney Yang (WSKY) added to risperidone on quality of life in patients with schizophrenia: a randomized controlled trial. [2009.09.28]
Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study. [2009.06]
Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). [2009.06]
Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. [2009.06]
A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study. [2009.05.26]
Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study. [2009.05]
|
